New Gene Therapy Offers Hope for Low Back Pain Relief

Introduction

Low back pain (LBP) remains a pervasive and debilitating condition, affecting millions globally and ranking as the leading cause of disability. Among the multifactorial causes of LBP, degeneration of the intervertebral disc (IVD) is particularly prominent. This degeneration results from a cascade of cellular and extracellular matrix changes, prominently involving the pro-inflammatory cytokine interleukin-1 (IL-1). However, despite its socioeconomic and personal toll, current treatments focus primarily on symptomatic relief without addressing the underlying pathophysiological mechanisms. In a promising advancement, PCRX-201, a novel gene therapy based on a high-capacity adenoviral vector, has been developed to deliver IL-1 receptor antagonist (IL-1Ra) directly to degenerated IVD tissues to mitigate IL-1-driven catabolic signaling.

Pathophysiology of IVD Degeneration and the Role of IL-1

The IVD is a complex structure composed of the nucleus pulposus (NP), annulus fibrosus (AF), and cartilaginous endplate (CEP). In healthy discs, native cells maintain a balance between matrix synthesis and degradation under hypoxic and low-nutrient conditions. However, this balance is disrupted during degeneration. The catabolic environment is marked by increased secretion of inflammatory cytokines, including IL-1β and IL-6, and degradative enzymes such as MMP3 and ADAMTS4. These molecular changes lead to apoptosis, senescence, matrix breakdown, and neoinnervation—hallmarks of painful disc degeneration.

IL-1 has emerged as a master regulator of this catabolic milieu. It exacerbates ECM degradation by upregulating matrix metalloproteinases and suppressing matrix genes such as aggrecan. In contrast, IL-1Ra, its natural antagonist, is insufficiently expressed in degenerated discs. Animal studies and genetic analyses further implicate IL-1 signaling dysregulation in disc degeneration, highlighting IL-1Ra as a critical therapeutic candidate.

PCRX-201: A High-Capacity Adenoviral Vector for IL-1Ra Delivery

PCRX-201 utilizes a helper-dependent serotype 5-based adenoviral vector designed to express IL-1Ra under the control of a nuclear factor-kappa B (NF-κB) promoter. This inducible system aligns with the inflammatory state of degenerate disc cells, which have elevated NF-κB activity, thus ensuring IL-1Ra expression in pathologically active cells. Previously tested in osteoarthritis models, PCRX-201 demonstrated effective disease modification, motivating its application in IVD degeneration.

Experimental Evaluation of PCRX-201 in Human IVD Cells and Tissue

The current study comprehensively evaluated the ability of PCRX-201 to transduce human NP cells derived from degenerated discs, enhance IL-1Ra expression, and suppress IL-1-driven catabolic pathways. Across a suite of in vitro and ex vivo models—including monolayer culture, 3D alginate bead culture, and tissue explants—the effects of PCRX-201 were assessed at different multiplicities of infection (MOI).

PCRX-201 successfully transduced degenerated human NP cells without affecting their metabolic activity. IL-1Ra levels were significantly elevated post-transduction, with MOI-dependent responses. Importantly, this effect persisted for up to ten weeks in 3D cultures, demonstrating the vector’s sustained expression capability.

PCRX-201 also decreased the expression and secretion of key catabolic factors. In both direct and paracrine assays, IL-1β, IL-6, MMP3, ADAMTS4, and VEGF levels were significantly reduced. Furthermore, aggrecan synthesis was enhanced, suggesting a shift toward matrix repair.

Validation in Ex Vivo NP Tissue Explants

The therapeutic potential of PCRX-201 was further validated through direct injection into human NP explants. After two weeks, PCRX-201-injected tissues showed significantly increased IL-1Ra expression and decreased catabolic protein levels. Immunohistochemical analysis confirmed reduced expression of IL-1β, MMP3, VEGF, and increased aggrecan within native NP cells. These findings underscore the efficacy of PCRX-201 in a physiologically relevant tissue model, closely mimicking the in vivo environment of the human disc.

Advantages and Future Directions

PCRX-201 represents a significant advancement over earlier gene therapy vectors due to its high-capacity backbone and NF-κB-responsive promoter. It addresses previous limitations seen in adenoviral systems that failed to transduce degenerated NP cells effectively. The current study’s use of low-oxygen, low-glucose, serum-free culture systems further enhances the translational relevance of the findings.

However, challenges remain. The long-term efficacy of PCRX-201 in vivo, particularly under biomechanical loading conditions, has yet to be determined. Additionally, although anti-catabolic effects were clearly demonstrated, future studies must address potential regenerative outcomes and safety in preclinical models before clinical translation.

Conclusion

This study provides compelling evidence that PCRX-201 can effectively transduce degenerate human IVD cells and tissues, elevating IL-1Ra levels and suppressing IL-1-driven catabolic signaling. By targeting the molecular root of IVD degeneration, PCRX-201 holds promise as a disease-modifying therapy for chronic low back pain. Its continued development may offer a novel therapeutic avenue that addresses the unmet clinical need for biologically restorative interventions in spinal disc degeneration.

Reference

Snuggs JW, Senter RK, Whitt JP, Jackson JD, Le Maitre CL. PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration. Gene Ther. 2025 Mar;32(2):93-105. doi: 10.1038/s41434-024-00504-7. Epub 2024 Nov 21. PMID: 39572769; PMCID: PMC11946895.

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)